Auk, further to your great research.
- The Anagrelide metabolite (3-hydroxy-anagrelide) is likely to be the main contributor to the negative cardiovascular effects of the drug. (TGA PAR ref)
- (Suda update 21 Feb 2019)
No liver metabolism = no metabolite = no cardio vascular impacts
All good really.
Now some good news that affects the share price (positively) would be appreciated Carter.
Anagrelide, page-200
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $162.8M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 15.0¢ | $117.3K | 755.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 324518 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 205828 | 3 |
View Market Depth
| Last trade - 15.06pm 04/07/2024 (20 minute delay) ? |
| ALA (ASX) Chart |